Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NanoString's Series D round brings in $20mm

Executive Summary

Molecular diagnostics company NanoString Technologies Inc. raised $20mm through its Series D round. New investors GE Healthymagination Fund (managed by GE Healthcare and GE Capital), BioMed Ventures, and former Genzyme CEO Henri Termeer were joined by returning backers Clarus Ventures, Draper Fisher Jurvetson, and OVP Venture Partners. Some of the proceeds will be used to advance development of NanoString's first molecular test, a PAM50 gene expression assay for breast cancer.
Deal Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register